Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mariko Brandon

Psychiatry Clearwater, FL Medical Doctor

NPI 1548603673 CMS profile 3570487

1437 S Belcher Rd, Clearwater, FL 33764

Open in the dashboard

General payments

$4,555

261 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mariko Brandon of Clearwater, FL is reported in the CMS Open Payments database as having received $4,555 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,162 79
2024 General $1,330 86
2023 General $1,565 67
2022 General $192 11
2021 General $43 3
2020 General $31 2
2019 General $232 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mariko Brandon
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mariko Brandon were reported at $1,162. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mariko Brandon Psychiatry median Middle half National median
2019 $232 $184 $59–$605 $163
2020 $31 $119 $36–$372 $114
2021 $43 $143 $43–$576 $132
2022 $192 $153 $50–$590 $149
2023 $1,565 $170 $56–$651 $160
2024 $1,330 $179 $57–$673 $164
2025 $1,162 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,180 59 payments
  2. Teva Pharmaceuticals USA, Inc. $1,103 98 payments
  3. Neurocrine Biosciences, Inc. $624 22 payments
  4. Otsuka America Pharmaceutical, Inc. $334 17 payments
  5. Vanda Pharmaceuticals Inc. $320 10 payments
  6. Janssen Pharmaceuticals, Inc $225 10 payments
  7. ITI, Inc. $210 10 payments
  8. Supernus Pharmaceuticals, Inc. $147 13 payments
  9. Indivior Inc. $113 5 payments
  10. Sunovion Pharmaceuticals Inc. $75 5 payments
  11. Other $224 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,555 261 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $967 49 payments
  2. UZEDY $670 41 payments
  3. INGREZZA $604 21 payments
  4. Austedo XR $365 54 payments
  5. HETLIOZ $320 10 payments
  6. FANAPT $320 10 payments
  7. VRAYLAR Neuroscience $244 12 payments
  8. CAPLYTA $210 10 payments
  9. ABILIFY MAINTENA $201 10 payments
  10. REXULTI $188 9 payments
  11. Other $1,351 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

3,908

Median for Psychiatry: 574

Drug cost

$792,538

Median for Psychiatry: $27,624

Branded share of claims

18.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Trinza Paliperidone Palmitate Brand 26 $238,488
Ingrezza Valbenazine Tosylate Brand 14 $117,322
Invega Sustenna Paliperidone Palmitate Brand 37 $102,822
Vraylar Cariprazine Hcl Brand 52 $73,947
Risperdal Consta Risperidone Microspheres Brand 52 $48,906
Aripiprazole Generic 174 $37,864
Rexulti Brexpiprazole Brand 20 $30,431
Lurasidone Hcl Generic 99 $23,085
Trintellix Vortioxetine Hydrobromide Brand 32 $21,165
Paliperidone Er Paliperidone Brand 14 $10,277

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$6,189

Medicare's payments for the services billed

Medicare patients

47

Average age 53

Services billed

128

27 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 51%
High blood pressure 45%
Arthritis 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $366
$366 52 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $253
$253 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $166
$166 14 —
PERSERIS
  • Indivior Inc. $95
$95 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $55
  • Lundbeck LLC $19
$74 20 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record